In MLLr-AML, although several impactful preclinical studies have demonstrated that the inhibition of ATM was a potent therapeutics, ATM inhibitors have not been tested at the clinical level [11, 12, 58]. This evidence concerns the gene ATM and acute myeloid leukemia.